



(51) International Patent Classification:

C07J 19/00 (2006.01) *A61K 31/395* (2006.01)
A61K 31/704 (2006.01) *A61P 27/06* (2006.01)

(21) International Application Number:

PCT/IL2014/050773

(22) International Filing Date:

27 August 2014 (27.08.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/871,328 29 August 2013 (29.08.2013) US

(71) Applicant: **YEDA RESEARCH AND DEVELOPMENT CO. LTD.** [IL/IL]; at the Weizmann Institute of Science, P.O. Box 95, 7610002 Rehovot (IL).

(72) Inventors: **KARLISH, Steven JD**; 6 Meonot Shein, Weizmann Institute of Science, 7610002 Rehovot (IL). **KATZ, Adriana**; c/o YEDA RESEARCH AND DEVELOPMENT CO. LTD., at the Weizmann Institute of Science, P.O. Box 95, 7610002 Rehovot (IL). **TAL, Daniel M.**; c/o YEDA RESEARCH AND DEVELOPMENT CO. LTD., at the Weizmann Institute of Science, P.O. Box 95, 7610002 Rehovot (IL).

(74) Agents: **WEBB & CO** et al.; P.O. Box 2189, 76121 Rehovot (IL).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: SELECTIVE INHIBITORS OF $\alpha 2$ ISOFORM OF Na,K-ATPase AND USE FOR REDUCTION OF INTRA-OCULAR PRESSURE

(57) Abstract: The present invention relates to digoxin and digitoxin derivatives that are selective inhibitors of the $\alpha 2$ isoform of Na,K-ATPase, and that reduce intra-ocular pressure. The invention further relates to uses of these derivatives for treating disorders associated with elevated intraocular pressure, such as glaucomas, and/or as cardiogenic agents.



WO 2015/029035 A1

SELECTIVE INHIBITORS OF $\alpha 2$ ISOFORM OF Na,K-ATPase AND USE FOR REDUCTION OF INTRA-OCULAR PRESSURE

FIELD OF THE INVENTION

5 The present invention relates to digoxin and digitoxin derivatives that are selective inhibitors of the $\alpha 2$ isoform of Na,K-ATPase, and that reduce intra-ocular pressure. The invention further relates to uses of these derivatives for treating disorders associated with elevated intraocular pressure, such as glaucomas, and/or as cardiotonic agents.

10

BACKGROUND OF THE INVENTION

 Glaucoma is a disease leading to irreversible blindness. Control of intra-ocular pressure (IOP) is the mainstay of current therapy of glaucoma, and is achieved by various drugs, such as β -blockers, prostaglandin analogues, $\alpha 2$ adrenergic receptor
15 agonists, cholinergic agonists and carbonic anhydrase inhibitors given topically or systemically. The topical route is preferable, provided the drug effectively permeates the cornea, because this minimizes systemic side-effects. Despite the selection of drugs available, uncontrolled IOP in many patients eventually makes surgical intervention necessary. Thus, fresh approaches to drug treatment of glaucoma are
20 highly desirable.

 The Na,K-ATPase is the motor for production of the aqueous humour in the ciliary body epithelium and, in principle, inhibition of the Na,K-ATPase should suppress the production of aqueous humour, and control IOP. Control of IOP is the mainstay of glaucoma therapy, but despite the selection of drugs available, fresh
25 approaches to drug treatments are highly desirable. Previously, intra-venous digoxin, a classical inhibitor of the Na,K-pump, used primarily to treat congestive heart failure, was considered for this role but was discarded due to systemic toxicity (1, 2).

 The Na,K-ATPase consists of α and β subunits ($\alpha\beta$) and accessory FXYD regulatory subunits. There are four isoforms of the $\alpha 1$ subunit ($\alpha 1$ -4) and three
30 isoforms of the β subunit ($\beta 1$ -3) expressed in a tissue-specific fashion. $\alpha 1$ is the common isoform that maintains Na and K gradients in all tissues, while $\alpha 2$ is

expressed mainly in muscle and astrocytes, and $\alpha 3$ in nerve cells. Human heart expresses $\alpha 1$ (c.70%) and both $\alpha 2$ and $\alpha 3$ isoforms (c.30%) and $\beta 1$. The ciliary epithelium in the eye is a functional syncytium consisting of apical pigmented cells (PE) oriented towards the blood and baso-lateral non-pigmented (NPE) cells oriented
5 towards the anterior chamber of the eye.

It is known that the primary Na,K-ATPase isoform of the PE is $\alpha 1\beta 1$ while that of the NPE is $\alpha 2\beta 3$ (3). Thus, in principle, topically applied $\alpha 2$ -selective cardiac glycosides that penetrate the intact eye and reach the ciliary epithelium could effectively reduce IOP, and provided that they penetrate the intact eye and reach the
10 ciliary epithelium, they could be applied topically. A potential advantage of topical application could be that systemic toxic effects typical of cardiac glycosides should be minimal.

Another possible application of an $\alpha 2$ -selective cardiac glycoside could be as an effective cardiotonic drug, with reduced cardiotoxicity, compared to known drugs
15 such as digoxin. Digitalis drugs such as digoxin have been used to treat heart failure for over two hundred years but are dangerous drugs with multiple side effects. There is now good evidence that selective inhibition of $\alpha 2$ is especially effective in enhancing cardiac excitation-contraction coupling and mediating cardiac glycoside-mediated positive inotropy (4). Inhibition of $\alpha 2$, which is a minor isoform, may not
20 cause cellular Ca overload, the hallmark of cardiac toxicity (5).

The isoform selectivity of a large number of known cardiac glycosides has been previously studied (6), using the yeast *P.pastoris* expressing Na,K-ATPase isoforms ($\alpha 1\beta 1$, $\alpha 2\beta 1$, $\alpha 3\beta 1$), and purified detergent-soluble isoform complexes of Na,K-ATPase (7-11). Dissociation constants, K_D , for digitalis glycosides, digoxin
25 and digitoxin, measured in ^3H -ouabain displacement assays in membranes, showed moderate selectivity (3-4-fold) for $\alpha 2/\alpha 3$ over $\alpha 1$. By contrast, aglycones such as digoxigenin and digitoxigenin showed no isoform selectivity. In assays of inhibition of Na,K-ATPase activity, measured with the purified isoform protein complexes, digoxin and digitoxin showed 3-4-fold lower K_i values for $\alpha 2$ compared to $\alpha 1$, with
30 $\alpha 3$ more similar to $\alpha 1$. Again, no aglycones of any cardiac glycosides tested showed isoform selectivity. For digoxin derivatives, with one to four digitoxose moieties the maximal $\alpha 2/\alpha 1$ selectivity was found for digoxin itself, with three digitoxose sugars.

By contrast to the digitalis glycosides, the K_D of ouabain showed some preference for $\alpha 1$ over $\alpha 2$ and similar K_i values for all three isoforms.

Based on these studies, it was determined that the sugar moiety of digoxin likely determines isoform selectivity, which is generally consistent with recent structures of Na,K-ATPase with bound ouabain (12-14). The unsaturated lactone ring and steroid portion of ouabain are bound between trans-membrane segments M1, M4, M5 of the α subunit, in which there are no amino-acid differences between isoforms. Assuming that the aglycones of all cardiac glycosides bind similarly, the implication is that isoforms cannot discriminate between any of the aglycones, as found experimentally. By contrast, the sugar is bound near extracellular loops, where there are a number of amino-acid differences between the isoforms. These residues might interact with the sugars of bound digoxin in an isoform-selective way.

There is an unmet need for new therapies for treating ocular disorders associated with elevated intraocular pressure, such as glaucomas, and for new cardiotonic agents, that are effective on the one hand, and that demonstrate an acceptable safety profile on the other.

SUMMARY OF THE INVENTION


The present invention relates to digoxin and digitoxin derivatives that are selective inhibitors of the $\alpha 2$ isoform of Na,K-ATPase over other isoforms of this enzyme. The compounds of the invention effectively reduce intra-ocular pressure, and are useful in the treatment of disorders associated with elevated intraocular pressure, such as glaucomas, and/or as cardiotonic agents.

It has previously been shown, using recombinant human $\alpha 1\beta 1$, $\alpha 2\beta 1$ and $\alpha 3\beta 1$ isoforms, that the classical inhibitor digoxin is partially $\alpha 2$ -selective and that the tri-digitoxose moiety is responsible for isoform-selectivity. The present invention is based on the discovery that modification of the third digitoxose increases selectivity for $\alpha 2$ over $\alpha 1$. Thus, the third digitoxose of digoxin has been chemically modified by periodate oxidation and reductive amination using a variety of R-NH₂ substituents, leading to a series of perhydro-1,4-oxazepine derivatives of digoxin. As demonstrated herein for the first time, several derivatives show increased selectivity for $\alpha 2$ over $\alpha 1$,

up to about 8-fold. Moreover, a molecular model of digoxin bound to the Na,K-ATPase suggests that perhydro-1,4-oxazepine derivatives of digoxin with different aliphatic substitutions could be relatively selective for the $\alpha 2\beta 3$ complex. Indeed, a series of aliphatic derivatives show improved selectivity for $\alpha 2\beta 3$ over $\alpha 1\beta 1$ - up to about 16-fold. Effects of topically applied cardiac glycosides on intra-ocular pressure in rabbits have been assessed by their ability to prevent or reverse an acute intraocular pressure increase induced by 4-aminopyridine or a selective agonist of the A3 adenosine receptor. The $\alpha 2$ -selective digoxin/digitoxin derivatives prevent or reverse ocular hypertension more efficiently as compared with digoxin itself, digoxigenin or ouabain. The digoxin/digitoxin derivatives of the present invention thus have the utility in the treatment of disorders associated with elevated intraocular pressure, such as glaucomas. As demonstrated herein, the most $\alpha 2\beta 3$ -selective derivative is especially effective. These observations are consistent with a major role of $\alpha 2\beta 3$ in aqueous humour production and suggest that, potentially, $\alpha 2$ -selective and especially $\alpha 2\beta 3$ -selective digoxin derivatives could be of interest as novel drugs for control of intraocular pressure.

Moreover, the $\alpha 2$ -selective digoxin/digitoxin derivatives of the present invention may show reduced toxicity, especially when applied topically. First, swelling of the cornea and lens should be minimal since only $\alpha 1$ and a minor amount of $\alpha 3$ but no $\alpha 2$ is expressed in the corneal epithelium and only $\alpha 1$ is expressed in the lens epithelium. Second, an $\alpha 2$ -selective digoxin/digitoxin derivative that reaches the general circulation from the eye should be only minimally cardiotoxic. Thus the present invention provides compounds that are not only potent as IOP-reducing agent, but that have the potential to be significantly less toxic than the parent compounds digoxin or digitoxin.

According to one aspect, the present invention relates to a compound represented by the structure of general formula (I):



I

wherein

- 5 R is selected from the group consisting of OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -(CR^bR^c)_nSi(R^a)₃, -(CR^bR^c)_n-C(=Y)-NR¹R², -(CR^bR^c)_n-C(=Y)-NHOH, -(CR^dR^e)_n-C(=Y)-COOR³; and -NHC(=Y)NR¹R²;

Y is O or S;

X is H or OH;

- 10 R¹, R² and R³ are each independently H or a C₁-C₄ alkyl;

R^a is a C₁-C₄ alkyl;

R^b, R^c and R^d are each independently selected from H, a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl;

R^e is selected from a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl; and

- 15 n is 0, 1 or 2;

including salts, hydrates, solvates, polymorphs, geometrical isomers, optical isomers, enantiomers, diastereomers, and mixtures thereof.

In one embodiment of formula (I), R is selected from the group consisting of CZ₃, -CZ₂CZ₃, -(CH₂)₂CH₃, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH₂CH(CH₃)₂,

- 20 -CH(CH₃)CH₂CH₃ and -C(CH₃)₃, wherein each Z is independently at each occurrence H or halogen. In one particular embodiment each Z is H or F.

In another embodiment of formula I, R is selected from the group consisting of -CH₂-C(=O)-NH₂, -CH₃, -(CH₂)₂-C(=O)-NH₂, -NHC(=O)-NH₂, OH, -CH(CH₃)CONH₂, -CH(CH₂OH)COOH, -CH(CH₂OH)CONH₂, -CH₂CH₃, -

- 25 CH₂CH₂CH₃, -CH₂C(CH₃)₂, -CH₂CF₃, -CH₂CONHOH, -NHCSNH₂, -CH₂CH₂F, -

$\text{CH}(\text{CH}_2)_3$, $-\text{C}(\text{CH}_3)_3$, and $-\text{CH}_2\text{-Si}(\text{CH}_3)_3$. Each possibility represents a separate embodiment of the present invention.

In one embodiment of formula (I), R^1 , R^2 and R^3 are each H. In another embodiment of formula (I), n is 1. In another embodiment of formula (I), n is 2. In
5 another embodiment of formula (I), Y is O. In another embodiment of formula (I), Y is S. In another embodiment of formula I, the $\text{C}_1\text{-C}_4$ hydroxyalkyl is CH_2OH (i.e., the compound is derived from serine or serinamide).

In one currently preferred embodiment, the compounds of the invention are derivatives of digoxin, i.e., X is OH in Formula I. In one embodiment, the present
10 invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}_2\text{-C(=O)-NH}_2$ (designated herein "DGlyN" or "compound 1"). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}_3$ (designated herein "DMe" or "compound 2"). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-(\text{CH}_2)_2\text{-C(=O)-NH}_2$ (designated herein "DPrN" or "compound 3"). In another embodiment,
15 the present invention relates to a compound of formula I wherein X is OH and R is $-\text{NHC(=O)-NH}_2$ (designated herein "DSCar" or "compound 4"). In another embodiment, the present invention relates to a compound of formula I wherein X and R are each OH (compound 6). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}(\text{CH}_3)\text{CONH}_2$ (compound 8). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}(\text{CH}_2\text{OH})\text{COOH}$ (compound 9). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}(\text{CH}_2\text{OH})\text{CONH}_2$ (compound 10). In another embodiment, the
25 present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}_2\text{CH}_3$ (compound 12). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-(\text{CH}_2)_2\text{CH}_3$ (compound 13). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}_2\text{CH}(\text{CH}_3)_2$ (compound 14). In another embodiment,
30 the present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}_2\text{CF}_3$ (designated herein "DMeCF₃" or "compound 15"). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is $-\text{CH}_2\text{C(=O)-NHOH}$ (compound 17). In another embodiment, the present invention

relates to a compound of formula I wherein X is OH and R is -NHCSNH₂ (compound 18). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is -CH₂CH₂F (compound 19). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is -CH(CH₃)₂ (compound 21). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is -C(CH₃)₃ (compound 22). In another embodiment, the present invention relates to a compound of formula I wherein X is OH and R is -CH₂-Si(CH₃)₃ (compound 23).

In another currently preferred embodiment, the compounds of the invention are derivatives of digitoxin, i.e., X is H in Formula I.

In one embodiment, the compound of the present invention is selective for $\alpha 2$ isoform of Na,K-ATPase over other isoforms of Na,K-ATPase. In other embodiments, the compound of the present invention is selective for the $\alpha 2\beta 1$, $\alpha 2\beta 2$ and/or $\alpha 2\beta 3$ isoform of Na,K-ATPase over the $\alpha 1\beta 1$ isoform of Na,K-ATPase, with each possibility representing a separate embodiment of the present invention.


In other embodiments, the present invention relates to a pharmaceutical composition comprising a compound of formula (I), and a pharmaceutically acceptable carrier or excipient. In some preferred embodiments, the pharmaceutical composition is an ophthalmic composition suitable for topical application to the eye in the form of an eye-drop solution, an ointment, a suspension, a gel or a cream. Each possibility represents a separate embodiment of the present invention.

Preferably, the composition further comprises at least one pharmaceutically acceptable agent selected from one or more of a stabilizer, a preservative, a chelating agent, a viscosity modifying agent, a buffering agent, and pH adjusting agent. Each possibility represents a separate embodiment of the present invention.

The compounds of the present invention are preferably selective for $\alpha 2$ isoform of Na,K-ATPase over other isoforms of Na,K-ATPase, i.e., they inhibit the $\alpha 2$ isoform (especially the $\alpha 2\beta 3$ isoform) over other isoforms of this enzyme, e.g., the $\alpha 1$ isoform. As such, they are useful in methods for reducing ocular hypertension, or for treating diseases associated with ocular hypertension, such as glaucoma. Thus, in one embodiment, the present invention relates to a method for reducing ocular hypertension, or for treating conditions associated with ocular hypertension such as

glaucoma, by administering to a subject in need of such a treatment an effective amount of a compound of formula I or a pharmaceutical composition according to the present invention. In other embodiments, the compound useful for reducing ocular hypertension, or for treating conditions associated with ocular hypertension such as

5 glaucoma, is a compound of formula IA:



wherein

R is selected from the group consisting of OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl,

-(CR^bR^c)_nSi(R^a)₃, -(CR^bR^c)_n-C(=Y)-NR¹R², -(CR^bR^c)_n-C(=Y)-NHOH,

10 -(CR^dR^e)_n-C(=Y)-COOR³; -NHC(=Y)NR¹R²; and -(CR^bR^c)_n-NH₂;

Y is O or S;

X is H or OH;

R¹, R² and R³ are each independently H or a C₁-C₄ alkyl;

R^a is a C₁-C₄ alkyl;

15 R^b, R^c, R^d and R^e are each independently selected from H, a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl; and

n is 0, 1 or 2;

including salts, hydrates, solvates, polymorphs, geometrical isomers, optical isomers, enantiomers, diastereomers, and mixtures thereof.

20 In one embodiment of formula (I), R is selected from the group consisting of CZ₃, -CZ₂CZ₃, -(CH₂)₂CH₃, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃ and -C(CH₃)₃, wherein each Z is independently at each occurrence H or halogen. In one particular embodiment each Z is H or F.

In another embodiment of formula (IA), R is selected from the group consisting of $-\text{CH}_2-\text{C}(=\text{O})\text{OH}$, $-\text{CH}_2-\text{C}(=\text{O})-\text{OCH}_3$ and $\text{CH}_2-\text{CH}_2-\text{NH}_2$. Each possibility represents a separate embodiment of the present invention.

In one embodiment of formula (IA), R^1 and R^2 are each H. In one embodiment of formula (IA), R^3 is H or CH_3 . In another embodiment of formula (IA), n is 1. In another embodiment of formula (IA), n is 2. In another embodiment of formula (IA), Y is O. In another embodiment of formula (IA), Y is S. In another embodiment of formula (IA), the $\text{C}_1\text{-C}_4$ hydroxyalkyl is CH_2OH (i.e., the compound is derived from serine or serinamide).

10 In one currently preferred embodiment, the compounds of the invention are derivatives of digoxin, i.e., X is OH in Formula IA. In one embodiment, the present invention relates to a compound of formula IA wherein X is OH and R is $-\text{CH}_2-\text{C}(=\text{O})\text{OH}$ (designated herein "DGly" or "compound 5"). In another embodiment, the present invention relates to a compound of formula IA wherein X is OH and R is -
15 $\text{CH}_2-\text{C}(=\text{O})-\text{OCH}_3$ (designated herein "DGlyMe" or compound 7). In another embodiment, the present invention relates to a compound of formula IA wherein X is OH and R is $-\text{CH}_2-\text{CH}_2-\text{NH}_2$ (designated herein "DEtDA or compound 11").

In another currently preferred embodiment, the compounds of the invention are derivatives of digitoxin, i.e., X is H in Formula IA.

20 The compound of formula IA may be administered in a pharmaceutical composition as described above for formula I. In some embodiments, the compounds encompassed by formula IA are selective for $\alpha 2$ isoform of Na,K-ATPase over other isoforms of Na,K-ATPase, i.e., they inhibit the $\alpha 2$ isoform over other isoforms of this enzyme, e.g., the $\alpha 1$ isoform. In other embodiments, the compounds encompassed by
25 formula IA are selective for the $\alpha 2\beta 1$, $\alpha 2\beta 2$ and/or $\alpha 2\beta 3$ isoform of Na,K-ATPase over the $\alpha 1\beta 1$ isoform of Na,K-ATPase, with each possibility representing a separate embodiment of the present invention.

In other embodiments, the present invention relates to the use of a compound of formula I or IA, or any compound encompassed by such formulae, for the
30 manufacture of a medicament for the reduction of ocular hypertension, or for treating diseases or disorders associated with ocular hypertension, such as glaucoma. Each possibility represents a separate embodiment of the present invention.

In other embodiments, the compounds of the invention are also useful as cardiotonic agents. Thus, in one embodiment, the present invention relates to a cardiotonic composition comprising of a compound of formula (I), or a compound of formula (IA). In another embodiment, the present invention relates to the use of a compound of formula (I) or formula (IA), as a cardiotonic agent. Each possibility represents a separate embodiment of the present invention.

The present invention will be better understood in conjunction with the description, figures and claims below.

10 BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 Technical features of the ocular hypertension experiments. New Zealand white rabbits were used for IOP measurements, IOP (mm Hg) of rabbits was measured using a calibrated Pneumatonometer (Model 30, Reichert technologies).

FIG. 2 Fig 2A: Synthesis of perhydro-1,4-oxazepine derivatives of digoxin. Fig 2B: Reverse phase HPLC purification of DGlyN, a representative compound of the present invention.

FIG. 3 Inhibition of Na,K-ATPase activity of purified isoform complexes by digoxin derivatives. Representative experiments for inhibition of Na,K-ATPase activity by DGlyN (A) DMe (B). $\alpha 1/\beta 1$ isoform $\square$; $\alpha 2/\beta 1$ isoform $\blacksquare$; $\alpha 3/\beta 1$ isoform $\blacktriangledown$. Lines are the fitted curves for a one-site inhibition model (see Example 4: Experimental Section).

FIG. 4 4-aminopyridine (4AP)-induced transient ocular hypertension in rabbits. Control $\blacksquare$; 4AP, 1 drop (40 mg/ml) $\square$; 4AP, 2 drops (40 mg/ml) Δ .

FIG. 5 Effects of DMe (A), DGlyN (B), digoxin (C), ouabain (D) and digoxigenin (E) on 4AP-induced ocular hypertension. Cardiac glycosides (CG's) (1 drop, 25 μ l) at the indicated concentrations were added to both eyes 30min before addition of 4AP (40mg/ml, 1 drop, 25 μ l). During this pre-incubation period there was little or no change in IOP. IOP was measured at the indicated times after addition of 4AP. In each experiment one rabbit was used for each concentration. The values are the mean of the IOP in both eyes.

FIG. 6 Comparison of the change in IOP with different CG's. The figure depicts the change in IOP (in mmHg) after 1.5 hours administration of 4AP and 0.1mM CG. The figure represents an average of 3 different experiments with the SEM.

FIG. 7 Time-course of effects of digoxin derivatives on IOP. In this experiment the IOP was elevated for 7-8 hours, by application of 4AP every 2 hours either in the absence of cardiac glycosides or after application of one drop of the cardiac glycoside (A and B), or one drop of cardiac glycoside was applied one hour after the first application of 4AP (C). All the other conditions and measurements are as described in Fig. 5.

FIG. 8 Effect of DMe, DGlyN and digoxigenin on IB-MECA-induced ocular hypertension. A. DMe at the indicated concentrations was added 30 minutes prior to IB-MECA. B. Digoxigenin, DGlyN, or DMe, 1mM were added 1.5 hours after the first addition of IB-MECA. C. Digoxigenin or DGlyN, 3mM were added 1.5 hours after the first addition of IB-MECA. 1 μ M IB-MECA was added at time zero and every 2 hours thereafter (arrows).

FIG. 9 Dissociation of digoxigenin, digoxin, DGlyN and DMe from the α 2 isoform. Fig. 9 depicts normalized data from representative experiments using the four different cardiac glycosides, obtained as described in the Methods.

FIG. 10 Model of Digoxin bound to the Na,K-ATPase. A. The model depicts the porcine α 1 β 1 complex (4HYT) with bound digoxin (3B0W). B. Detail of residues in proximity to bound digoxin (numbering is for porcine α 1 and β 1). C and D depict β 1 versus β 3 showing β 1Gln84 and β 3Val89.

FIG. 11 shows the expression of α 2 β 3 and α 2 β 2 as well as α 2 β 1 and α 1 β 1 isoform complexes in Coomassie blue stained gels. The proteins were denatured prior to treatment with PNGase.

FIG. 12 K-activation of Na,K-ATPase activity of α 1 β 1, α 2 β 1, α 2 β 2, α 2 β 3 isoform complexes. The Figure shows representative curves.

FIG. 13 Inhibition of the Na,K-ATPase activity of α 1 β 1, α 2 β 1, α 2 β 2, α 2 β 3 by digoxin. The Figure shows representative curves.

FIG. 14 Inhibition of the Na,K-ATPase activity of α 1 β 1, α 2 β 1, α 2 β 2, α 2 β 3 by DIB. The Figure shows representative curves.

FIG. 15 Inhibition of acute ocular hypertension by DIB. The Figure represents the average effects of different concentrations of DIB in four experiments.


DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise specified, "a" or "an" means "one or more".

- 5 The present invention relates to digoxin and digitoxin derivatives that are selective inhibitors of the $\alpha 2$ isoform of Na,K-ATPase. The compounds of the invention effectively reduce intra-ocular pressure, and are useful in the treatment of disorders associated with elevated intraocular pressure, such as glaucomas, and/or as cardiotonic agents.
- 10 The term "selective inhibitor of the $\alpha 2$ isoform of Na,K-ATPase" means that the compound inhibits the $\alpha 2$ isoform of Na,K-ATPase to a greater degree than the other isoforms, e.g., the $\alpha 1$. In some embodiments, the compounds described herein are selective for the $\alpha 2\beta 1$, $\alpha 2\beta 2$ and/or $\alpha 2\beta 3$ isoform of Na,K-ATPase over the $\alpha 1\beta 1$ isoform of Na,K-ATPase. In some embodiments, the selectivity of the compound for
- 15 the $\alpha 2$ isoform of Na,K-ATPase (e.g., $\alpha 2\beta 1$, $\alpha 2\beta 2$ and/or $\alpha 2\beta 3$ isoform) is up to about 20 fold over other isoforms, e.g., up to 16 fold, 8 fold, 5 fold or 2 fold greater inhibition of the $\alpha 2$ isoform over other isoforms of this enzyme.

Compounds

- 20 According to one aspect, the present invention relates to a compound represented by the structure of general formula (I):



I

wherein

R is selected from the group consisting of OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, $-(CR^bR^c)_nSi(R^a)_3$, $-(CR^bR^c)_n-C(=Y)-NR^1R^2$, $-(CR^bR^c)_n-C(=Y)-NHOH$, $-(CR^dR^e)_n-C(=Y)-COOR^3$; and $-NHC(=Y)NR^1R^2$;

5 Y is O or S;

X is H or OH;

R¹, R² and R³ are each independently H or a C₁-C₄ alkyl;

R^a is a C₁-C₄ alkyl;


10 R^b, R^c and R^d are each independently selected from H, a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl;

R^e is selected from a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl; and

n is 0, 1 or 2;

including salts, hydrates, solvates, polymorphs, geometrical isomers, optical isomers, enantiomers, diastereomers, and mixtures thereof.

15 According to another aspect, the present invention relates to a compound represented by the structure of general formula (IA):



wherein

20 R is selected from the group consisting of OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, $-(CR^bR^c)_nSi(R^a)_3$, $-(CR^bR^c)_n-C(=Y)-NR^1R^2$, $-(CR^bR^c)_n-C(=Y)-NHOH$, $-(CR^dR^e)_n-C(=Y)-COOR^3$; $-NHC(=Y)NR^1R^2$; and $-(CR^bR^c)_n-NH_2$;

Y is O or S;

X is H or OH;

25 R¹, R² and R³ are each independently H or a C₁-C₄ alkyl;

R^a is a C₁-C₄ alkyl;

R^b, R^c, R^d and R^e are each independently selected from H, a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl; and

n is 0, 1 or 2; including salts, hydrates, solvates, polymorphs, geometrical isomers, optical isomers, enantiomers, diastereomers, and mixtures thereof.

In some currently preferred embodiment, the compound is selected from the group consisting of a digoxin derivative (X is OH) or a digitoxin derivative (X is H). Several preferred compounds of formula (I) or (IA) are exemplified below, with each possibility representing a separate embodiment of the present invention.

10 A compound of formula (1), in which X is OH and R is derived from glycineamide (R = -CH₂C(=O)-NH₂), abbreviated herein "DGlyN".

A compound of formula (2), in which X is OH and R is CH₃, abbreviated herein "DMe".

15 A compound of formula (3), in which X is OH and R is derived from propionamide (R = -CH₂CH₂C(=O)-NH₂), abbreviated herein "DPrN".

A compound of formula (4), in which X is OH and R is derived from semicarbazide (R = -NHC(=O)-NH₂), abbreviated herein "DSCar".

A compound of formula (5), in which X is OH and R is derived from glycine (R = -CH₂C(=O)OH), abbreviated herein "DGly".

20 A compound of formula (6), in which X and R are each is OH, abbreviated herein "DOH".

A compound of formula (7), in which X is OH and R is derived from glycine methyl ester (R = -CH₂-C(=O)-OCH₃), abbreviated herein "DGlyMe".

25 A compound of formula (8), in which X is OH and R is derived from alanineamide (R = -CH(CH₃)CONH₂), abbreviated herein "DAIaN".

A compound of formula (9), in which X is OH and R is derived from serine (R = -CH(CH₂OH)COOH), abbreviated herein "DSer".

A compound of formula (10), in which X is OH and R is derived from serinamide (R = -CH(CH₂OH)CONH₂), abbreviated herein "DSerN".

A compound of formula (11), in which X is OH and R is derived from ethylene diamine ($R = -CH_2-CH_2-NH_2$), abbreviated herein "DEtDA".

A compound of formula (12), in which X is OH and R is $-CH_2CH_3$ abbreviated herein "DEt".

5 A compound of formula (13), in which X is OH and R is $-(CH_2)_2CH_3$ abbreviated herein "DPr" or "DP".

A compound of formula (14), in which X is OH and R is $-CH_2CH(CH_3)_2$ abbreviated herein "DiBu".

10 A compound of formula (15), in which X is OH and R is derived from 2,2,2-trifluoroethyl ($R = -CH_2CF_3$), abbreviated herein "DMeCF₃".

A compound of formula (17) wherein X is OH and R is $-CH_2C(=O)-NHOH$, abbreviated herein "DGlyNHOH".

A compound of formula (18) wherein X is OH and R is derived from semithiocarbazide ($R = -NHCSNH_2$), abbreviated herein "DSSCar".

15 A compound of formula (19) wherein X is OH and R is $-CH_2CH_2F$, abbreviated herein "DCH₂CH₂F".

A compound of formula (21) wherein X is OH and R is $-CH(CH_3)_2$, abbreviated herein "DiPro" or "DIP".

20 A compound of formula (22) wherein X is OH and R is $-C(CH_3)_3$, abbreviated herein "DtBu".

A compound of formula (23) wherein X is OH and R is methyl (trimethylsilyl) ($-CH_2-Si(CH_3)_3$), abbreviated herein "DTMS".

These and other representative compounds are shown hereinbelow in Table 1.

25 The term "C₁-C₆ alkyl" group refers to any saturated aliphatic hydrocarbon, including straight-chain and branched-chain groups containing between 1 and 6 carbon atoms. The term "C₁-C₄ alkyl" group refers to any saturated aliphatic hydrocarbon, including straight-chain and branched-chain groups containing between 1 and 4 carbon atoms. Non-limiting examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-pentyl, 3-pentyl, neopentyl, 1-hexyl, 2-hexyl and
30 3-hexyl. The alkyl group may be substituted or unsubstituted.

The term "halogen" refers to fluoro, chloro, bromo or iodo.

All stereoisomers, optical and geometrical isomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at one or more of the atoms. Consequently, the compounds can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The present invention contemplates the use of any racemates (i.e. mixtures containing equal amounts of each enantiomers), enantiomerically enriched mixtures (i.e., mixtures enriched for one enantiomer), pure enantiomers or diastereomers, or any mixtures thereof. The chiral centers can be designated as R or S or R,S or d,D, l,L or d,l, D,L. Compounds comprising amino acid residues (e.g., glycine or glycineamide) include residues of D-amino acids, L-amino acids, or racemic derivatives of amino acids.

One or more of the compounds of the invention, may be present as a salt. The term "salt" encompasses both basic and acid addition salts, and include salts formed with organic and inorganic anions and cations. The term "organic or inorganic cation" refers to counter-ions for an acid. The counter-ions can be chosen from the alkali and alkaline earth metals, (such as lithium, sodium, potassium, barium, aluminum and calcium), ammonium and the like. Furthermore, the term includes salts that form by standard acid-base reactions of basic groups and organic or inorganic acids. Such acids include hydrochloric, hydrofluoric, hydrobromic, trifluoroacetic, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, cholic, pantoic, mucic, D-camphoric, phthalic, tartaric, salicylic, methanesulfonic, benzenesulfonic, p-toluenesulfonic, sorbic, picric, benzoic, cinnamic, and like acids.

The present invention also includes solvates of the compounds of the present invention and salts thereof. "Solvate" means a physical association of a compound of the invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates and the like. "Hydrate" is a solvate wherein the solvent molecule is water.

The present invention also includes polymorphs of the compounds of the present invention and salts thereof. The term “polymorph” refers to a particular crystalline state of a substance, which can be characterized by particular physical properties such as X-ray diffraction, IR spectra, melting point, and the like.

5

Pharmaceutical Compositions and Therapeutic Uses

In some embodiments, the present invention provides a method for treating disorders associated with elevated intraocular pressure, and in particular for treating glaucoma, by administering an effective amount of a pharmaceutical compositions
10 comprising a compound of formula I and/or IA as the active ingredient (e.g., compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 19, 21, 22 or 23) and a pharmaceutically acceptable carrier.

In other embodiments, the present invention provides a method for reducing elevated intraocular pressure, by administering an effective amount of a
15 pharmaceutical composition comprising a compound of formula I and/or IA as the active ingredient (e.g., compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 19, 21, 22 or 23) and a pharmaceutically acceptable carrier.

Preferably, the pharmaceutical compositions of the invention is an ophthalmic composition which is administered topically onto the eye of a patient for facilitating
20 effective intraocular levels of the drug and for preventing unnecessary drug level in other organs. Such a non-systemic, site-specific administration reduces the side effects associated with the drugs. However, oral or otherwise systemic administration in a dosage effective for reducing the intraocular pressure is also possible. For example, the composition may be administered by a dermal patch for extended
25 release.

When administration is topical, the pharmaceutical compositions containing the digoxin derivative of formula I or IA may be formulated in various therapeutic forms suitable for topical delivery, including solutions, suspensions, emulsions and gels. The carrier in these formulations may be any pharmaceutical acceptable carrier
30 such as saline, buffered saline, carbopol gel, mineral oil and the like. The formulations can be prepared in accordance with known procedures for the preparation of ophthalmic formulations. Preferably, the concentration of the digoxin derivative in the

pharmaceutical compositions is in the range of about 1 to about 5,000 µg/ml, preferably from about 80 to about 800 µg/ml and the formulation is preferably applied in one to four doses per day wherein each dose contains about 1 to 125 µg of the digoxin derivative, more preferably from about 2 to about 20 µg of digoxin derivative.

5 The topical pharmaceutical compositions may be in the form of eye-drops to be applied by instillation into the eye or may be in the form of a viscous ointment, gel or cream to be applied by an ointment onto the ocular surface and may contain control release means for facilitating sustained release over a prolonged period of time.

10 The compositions may further include non-toxic auxiliary pharmaceutically acceptable substances such as stabilizers, preservatives, chelating agents, viscosity modifying agents, buffering agents and/or pH adjusting agents. Additionally, the compositions may contain other ophthalmic active agents such as antibacterial agents, comfort enhancers, antioxidants, intra-ocular pressure (IOP)-reducing drugs and the like.

15 In accordance with other embodiments, the digoxin/digitoxin derivative may be loaded into a drug-delivery device to be inserted or implanted into the eye of the patient for allowing releasing of the drug in a controlled and continuous rate, by dissolving, diffusion or leaching, thus maintaining effective therapeutic concentration over a prolonged period of time. The drug-delivery device may be for example a
20 biocompatible thin film loaded with the active agent, inserted for example beneath the lower eyelid.

 Another possible application of an α 2-selective cardiac glycoside is as an effective cardiotonic drug, with reduced cardiotoxicity, compared to known drugs such as digoxin. Thus, in other embodiments, the present invention provides
25 cardiotonic compositions comprising a compound of formula I and/or IA as the active ingredient (e.g., compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 19, 21, 22 or 23) and a pharmaceutically acceptable carrier. In accordance with this embodiment, the compounds according to the invention may therefore be formulated for oral, buccal, topical, parenteral or rectal administration.

30 For oral administration, the composition may be provided, for example, in the form of tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional methods using acceptable diluents. For buccal administration, the

composition may be provided in the form of conventionally formulated tablets or sachets.

The compounds according to the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection
5 may be provided in the form of ampoules containing single doses or they may be provided in multiple dose containers with added preservative. The composition may be in the form of suspensions, solutions and the like.

Alternatively, the active ingredient may be provided in powder form to be reconstituted before use with a suitable carrier. For topical use, the compounds
10 according to the invention may be formulated in the conventional manner as ointments, creams, gels, lotions, powders or sprays.

The principles of the invention, using an albumin conjugate isoflavone derivative bound to a bioactive moiety such as an imaging agent or a therapeutic agent for selective delivery to cells susceptible to isoflavone according to the present
15 invention, may be better understood with reference to the following non-limiting examples.


EXAMPLES

20 **EXAMPLE 1: Synthesis and testing of perhydro-1,4-oxazepine derivatives of digoxin**

Perhydro-1,4-oxazepine derivatives were prepared according to the method described in (15). Fig 2A shows the synthetic route involving (a) selective periodate oxidation of the third digitoxose moiety and (b) reductive amination of the dialdehyde
25 using the free amine (R-NH₂) plus NaCNBH₃, for the case of glycinamide. Compounds were purified by HPLC, as seen for the representative example of the DGlyN derivative in Fig 2B. Progress of both stages of the reactions as well as purification of compounds was monitored routinely by thin layer chromatography and mass spectrometry measurements. ¹H and ¹³C NMR spectra and full assignments were
30 obtained for several derivatives and will be published elsewhere. Structures of representative compounds of the invention are shown in Table 1. For verification of the structures, masses of the purified compounds were then determined. The table

shows the structures of the different amine substituents, names, and theoretical and experimentally found masses of fifteen digoxin derivatives, and also the glycine derivative of bis-digitoxose digoxigenin. Mass spectra were obtained in a Micromass ZQ 4000 spectrometer, with Electro Spray Ionization.

5 **Table 1 Structures, names and masses of perhydro-1,4-oxazepine derivatives of digoxin**



R =	Derivative Chem. Name	Name Abbreviation	Theoretical Exact Mass	Mass Found (M + Na ⁺)
-CH ₂ CONH ₂ (1)	glycinamide	DGlyN	820.47	843.42
-CH ₃ (2)	methylamine	DMe	777.47	800.57
-CH ₂ CH ₂ CONH ₂ (3)	propionamide	DPrN	834.49	857.30
-NHCONH ₂ (4)	semicarbazide	DSCar	821.47	844.37
-CH ₂ COOH (5)	glycine	DGly	821.46	844.44
-OH (6)	hydroxylamine	DOH	779.45	802.47
-CH ₂ COOCH ₃ (7)	glycine methyl ester	DGMe	835.47	858.51
-CH(CH ₃)CONH ₂ (8)	alaninamide	DAlaN	834.49	857.56
-CH(CH ₂ OH)COOH (9)	serine	DSer	851.47	874.61
-CH(CH ₂ OH)CONH ₂ (10)	serinamide	DSerN	850.48	873.59
-CH ₂ CH ₂ NH ₂ (11)	ethylenediamine	DEtDA	806.49	829.48
-CH ₂ CH ₃ (12)	ethylamine	DEt	791.48	814.52
-CH ₂ CH ₂ CH ₃ (13)	propylamine	DPr	805.50	828.27
-CH ₂ C(CH ₃) ₂ (14)	isobutylamine	DiBu	819.51	842.41
-CH ₂ CF ₃ (15)	2,2,2-trifluoroethylamine	DMeCF ₃	845.45	868.14
bis-CH ₂ COOH (16)	bis-glycine*	DbisGly	691.39	714.40
-CH ₂ CONHOH (17)	glycine hydroxamate	DGlyNHOH	836.47	858.51
-NHCSNH ₂ (18)	semithiocarbazide	DSSCar	821.47	844.37
-CH ₂ CH ₂ F (19)	2-fluoroethylamine	DCH ₂ CH ₂ F	809.47	832.46
-CH(CH ₂) ₃ (21)	isopropylamine	DiPro	805.50	828.53
-C(CH ₃) ₃ (22)	t-butylamine	DtBu	819.51	842.66
-CH ₂ Si(CH ₃) ₃ (23)	(Trimethylsilyl)methylamine	DTMS	849.51	872.50

* bis-glycine refers to a glycine derivative of bis-digitoxose digoxigenin.

10 EXAMPLE 2: Inhibition of Na,K-ATPase activity

Fig. 3 shows curves for inhibition of Na,K-ATPase activity of purified human isoforms ($\alpha 1\beta 1$, $\alpha 2\beta 1$ and $\alpha 3\beta 1$) of two derivatives, DGlyN (compound 1) and DMe (compound 2), with improved selectivity for $\alpha 2$ compared to digoxin itself. Table 2 provides information on the inhibitory effects of sixteen digoxin perhydro-1-4-oxazepine derivatives, in accordance with the present invention. The data in Table 2 show that the isoform selectivity ratios ($K_{i\alpha 1/\alpha 2}$) of several derivatives: DGlyN (7.45 ± 0.46), DMe (6.47 ± 0.71), DGly (5.1 ± 0.54), DPrN (5.28 ± 0.75) and DSCar (4.98 ± 1.2) are significantly greater than that of digoxin (3.44 ± 0.34). For these compounds, the K_i values for both $\alpha 1$ and $\alpha 2$ are lower than for digoxin, but the effect is greater for $\alpha 2$ compared to $\alpha 1$. Consequently, the ratio $K_{i\alpha 1/\alpha 2}$ is higher for the compounds of the invention compared to digoxin. In all cases the K_i for $\alpha 3$ is closer to that for $\alpha 1$ than to $\alpha 2$. This feature is seen clearly for DMe and DGlyN in Fig. 3, and is also applicable to the other compounds encompassed by Formula (I). Thus, it is primarily the $K_{i\alpha 1/\alpha 2}$ that is affected by the modification of the third digitoxose. The K_i values of several derivatives in Table 2 (e.g. DEt) are significantly lower than for digoxin itself but a differential effect between the isoforms was not observed, so that the selectivity ratio was not improved. The K_i values of several other derivatives in Table 2 (e.g. DEtDA) are significantly lower than for digoxin itself and some differential effect was observed. In other cases (e.g. DOH and DSer) the K_i values were higher than for digoxin and the selectivity for $\alpha 2$ was not improved. The result in Table 2 that the glycine derivative of bis-digitoxose digoxigenin (DbisGly) shows lower selectivity for $\alpha 2$ over $\alpha 1$ compared to the glycine derivative of the tri-digitoxose (DGly) shows that modification of the third digitoxose residues is optimal for this effect, consistent with a similar conclusion in (6). In summary, the strategy of modifying the third digitoxose moiety produced compounds with an improved ratio $K_{i\alpha 1/\alpha 2}$, reaching over twice the value of digoxin in the case of the most $\alpha 2$ -selective derivatives, DGlyN and DMe..

Table 2: Ki values for inhibition of Na,K-ATPase activity of isoforms $\alpha 1\beta 1$ and $\alpha 2\beta 1$ with selectivity ratios

CG	Ki $\pm$ S.E.			Selectivity ratio	
	$\alpha 1$	$\alpha 2$	p value, n $\alpha 2$ to $\alpha 1$	Ki $\alpha 1/\alpha 2 \pm$ S.E.	p value relative to digoxin
Ouabain	97 $\pm$ 4.3	90 $\pm$ 14		1.08 $\pm$ 0.17	
Digoxigenin	139 $\pm$ 17	130 $\pm$ 13.5		1.07 $\pm$ 0.17	-
Digoxin	189 $\pm$ 11	55 $\pm$ 4.4	0.0001, 12	3.44 $\pm$ 0.34	
DGlyN (1)	152 $\pm$ 5.5	20.4 $\pm$ 1	0.0001, 8	7.45 $\pm$ 0.46	0.0001
DMe (2)	101 $\pm$ 4.4	15.6 $\pm$ 2.3	0.0001, 8	6.47 $\pm$ 0.71	0.0001
DPrN (3)	249 $\pm$ 37	47 $\pm$ 7.8	0.006, 3	5.28 $\pm$ 0.75	0.0254
DSCar (4)	102 $\pm$ 23	20 $\pm$ 3.6	0.014, 4	4.98 $\pm$ 1.2	0.029
Dgly (5)	124 $\pm$ 8.6	25 $\pm$ 3.9	0.0003, 6	5.10 $\pm$ 0.54	0.0167
DOH (6)	311 $\pm$ 18.5	134 $\pm$ 35	0.046, 3	2.32 $\pm$ 0.62	-
DGIMe (7)	540 $\pm$ 102	128 $\pm$ 11	0.052, 3	4.22 $\pm$ 0.88	
DAlaN (8)	232 $\pm$ 28	67 $\pm$ 8.1	0.005, 3	3.46 $\pm$ 0.59	-
DSer (9)	316 $\pm$ 109	145 $\pm$ 28.5	0.269, 3	2.18 $\pm$ 0.86	-
DSerN (10)	242 $\pm$ 15	144 $\pm$ 3.5	0.033, 3	1.68 $\pm$ 0.13	-
DEtDA (11)	69 $\pm$ 10	16.7 $\pm$ 2.1	0.003, 4	4.10 $\pm$ 0.82	
DEt (12)	53 $\pm$ 3.4	18.5 $\pm$ 4.9	0.0045, 5	2.88 $\pm$ 0.78	-
DMeCF ₃ (15)	199 $\pm$ 33	44 $\pm$ 7	0.01, 3	4.50 $\pm$ 1.0	-
DbisGly (16)	80 $\pm$ 5.5	34.9 $\pm$ 12	0.075, 3	2.29 $\pm$ 0.80	-
Dbis* (20)	196 $\pm$ 8.5	74 $\pm$ 5	0.006, 3	2.65 $\pm$ 0.81	-

*Dbis is digoxigenin bis digitoxide.

- 5 The CG abbreviation corresponds to the following starting amine: DOH-hydroxylamine; DGly-glycine; DGIMe-glycine methyl ester; DGlyN-glycinamide; DAlaN-alaninamide; Dser-serine; DSerN-serinamide; DSCar-semicarbazide; DPrN-propionamide; DEtDA-ethylene diamine; DMe-methylamine; DEt-ethylamine; DMeCF₃-2,2,2-trifluoroethylamine; DbisGly- bis-digitoxoside glycine. p values were
- 10 calculated by the t-test and denoted as *p<0.05, **P<0.01, ***p<0.001. n , number of independent experiments. p ($\alpha 2$ v $\alpha 1$) indicates the significance of differences between Ki $\alpha 2\beta 1$ and Ki $\alpha 1\beta 1$. p (v digoxin) indicates the significance of the difference of the selectivity ratio (Ki $\alpha 1\beta 1$ / Ki $\alpha 2\beta 1$) compared to the (Ki $\alpha 1\beta 1$ / Ki $\alpha 2\beta 1$) of digoxin.

15 EXAMPLE 3: Reduction of intra-ocular pressure by topically applied digoxin

and perhydro-1,4-oxazepine derivatives.

Intra-ocular pressure in rabbits was measured using of a "Reichert Model 30™ Pneumatonometer" after anesthetizing the cornea with local anesthetic. Two different pharmacological agents were used to induce acute elevation of IPO and determine whether topically applied glycosides of the present invention are able to counter such an effect. First, IOP elevation was induced acutely with 4-aminopyridine (4AP), which has been previously reported to acutely and transiently raise IOP in rabbits eyes by 4-8 mm Hg from a resting IOP of 22-24mmHg (16). The mechanism of ocular hypertension induced by 4AP, which is a well-known blocker of a voltage-dependent K channel, was shown to involve release of norepinephrine from sympathetic nerves of the iris-ciliary body, leading to an increased rate of aqueous humour inflow. Fig 4 confirms the basic effect of 4AP. One or two drops of 4AP in each eye raised the IOP by 3-6mm Hg, and the effect was dissipated after 5 hours.

Since the IOP reflects a balance of the inflow and outflow of aqueous humour, reduction of the increased 4AP-induced inflow of aqueous humour by cardiac glycosides should prevent the increase in IOP. Thus, the standard experimental design to test effects of cardiac glycosides involved topical application of the compounds (1 drop in each eye) 30 minutes prior to application of 4AP and measurement of IOP every 30 minutes over five hours. Fig. 5 shows effects of digoxin, DGlyN and DMe, digoxigenin and ouabain on IOP using this protocol. Each experiment was done three times, but the figures depict a representative experiment using a different rabbit for each concentration of the cardiac glycoside. The plotted values represent the average pressures for both eyes although the values are similar in each eye measured separately. Digoxin (Fig. 5C) at a high concentration (1 mM) is able to prevent the 4AP-induced rise in IOP, while 0.25mM digoxin is poorly effective. By comparison, both DGlyN and DMe (Fig. 5A, B), the most α 2-selective of the new perhydro-1,4-oxazepine derivatives, are effective at much lower concentrations (0.05-0.1 mM) than digoxin. Similarly the aglycone of digoxin, digoxigenin, effectively reduced IOP at lower concentrations than digoxin (Fig. 5E). Finally, ouabain, a widely used water-soluble cardiac glycoside, somewhat reduced IOP only at 1mM while lower concentrations were poorly effective (Fig. 5D).

Fig. 6 compares the relative effects of DGlyN, DMe, digoxigenin, digoxin and ouabain, on IOP all at 0.1mM and one time point. The data represent the average

effect $\pm$ SEM of the three separate experiments (i.e. 6 eyes in all) and confirm the order as DGlyN $\approx$ DMe $\approx$ digoxigenin>digoxin>ouabain.

Over time, the cardiac glycosides that penetrate to the ciliary epithelium after a single application will be washed out of the eye into the general circulation and so the effect on IOP will dissipate. Although Figs. 5 and 6 demonstrate that the cardiac glycosides reduce IOP with greater or less efficacy, by this experimental protocol the longevity of the effect cannot be evaluated due to the transient nature of the 4AP effect itself. Thus, additional experiments were conducted in which the effect of a single drop of digoxin, digoxigenin, DGlyN, DMe or ouabain was compared when 4AP was then added every two hours so as to maintain the IOP at the elevated level for 7-8 hours, even in the absence of the cardiac glycosides (Fig. 7). By this protocol, the reduction of IOP is indeed seen to be transient in Fig 7. Fig. 7A shows a representative experiment with DMe that demonstrates a clear dependence of the wash-out time on concentration. IOP is held at the low level for 5.8, 4.5 and 2.5 hours for 2mM, 0.5mM and 0.2mM respectively, before the IOP rises back to the elevated level with 4AP. Other experiments showed that at equal concentrations the wash-out time for DGlyN is slightly faster than for DMe. Notable differences in wash-out times were detected between DMe, DGlyN, digoxigenin, digoxin and ouabain when they were applied at equal concentrations (1mM). As seen in Fig 7B, DMe maintained IOP at the low level for about 5.5 hours, by comparison with 3.5 hours for DGlyN, about 2 hours for digoxigenin and only 1 hour for digoxin. Ouabain is washed out at a rate between that of digoxin and digoxigenin. The data is not shown for clarity. In short, the most α 2-selective derivatives DMe (compound 2) and DGlyN (compound 1) produce the longest acting effect to reduce IOP, compared to either digoxin (a less α 2-selective cardio-glycoside (CG)), or digoxigenin a non-selective CG.

Fig. 7C shows that DGlyN and DMe rapidly reverse pre-established ocular hypertension. DGlyN or DMe (0.1 or 1mM) were applied one hour after the first application of 4AP, which was added every two hours. Evidently, within 30 minutes DGlyN and DMe reversed the initial rise in IOP, indicating that the compounds permeate the cornea and bind to the pump sufficiently fast to have this effect. The normalized IOP was then maintained for at least 4 hours, as in Fig. 7B. Independently of the superior effects of α 2-selective derivatives at low concentrations compared to digoxin itself, the rapid onset of the effects of DGlyN and DMe is suggestive of

inhibition of $\alpha 2$, because $\alpha 2$ is known to bind cardiac glycosides much more rapidly than $\alpha 1$ (17).

To verify that digoxin derivatives inhibits aqueous humour inflow directly and not act indirectly by, for example, interfering with the 4AP itself, topical IB-MECA was used. IB-MECA induces acute ocular hypertension by a different and well-defined mechanism. Namely, IB-MECA is a selective agonist of the A₃-adenosine receptor, and rises aqueous humour inflow and IOP by activating Cl channels of the NPE cells (18, 19). A single drop of IB-MECA (1 μ M) induced a significant but transient increase in IOP, while repeated application each 2 hours maintained increased IOP over 4-5 hours (see Fig. 8A Control). Figure 8A depicts the effects of DMe (0.1-1mM) applied prior to the IB-MECA, and a similar result was obtained for DGlyN (not shown). Figure 8B depicts effects of digoxigenin, DGlyN and DMe (1mM) applied after the IB-MECA. The effects of digoxigenin, DGlyN and DMe at 1mM were almost the same as seen with 4AP in Fig. 7, obviously excluding the notion that CG's interfere with the action of 4AP itself. In addition, the duration of the effect was significantly greater for DMe and DGlyN than for digoxigenin. Furthermore, when the concentration of DGlyN and digoxigenin was raised to 3 mM, the difference in duration of the effect was greatly amplified compared to the experiment with 1mM.

Corneal thickness was also measured after application of Digoxin (1mM), DGlyN (0.5mM), DMe (0.5mM) and ouabain (1mM) after 4AP. At least over a time scale of 4 hours, the corneal thickness, measured in microns, was not significantly affected. Thus, in this study, no change in corneal thickness was detected (Table 3), indicative of lack of local toxic effects. In addition neither redness nor local irritation were observed in the conjunctiva or cornea. Similar results were obtained with CG's applied after IB-MECA.

Table 3: Pachymetry-Corneal thickness before and after application of cardiac glycosides

Time	Digoxin 1mM		DGlyN 0.5mM		DMe 0.5mM		Ouabain 1mM	
	RE	LE	RE	LE	RE	LE	RE	LE
0h	462	470	496	498	507	465	461	455
2h	422	450	476	462	476	440	405	409
4h	451	467	454	455	498	453	414	422

RE, right eye LE, left eye. Corneal thickness is given in microns. Each value represents the average of three independent measurements.

5

EXAMPLE 4: Dissociation of cardiac glycosides from $\alpha 2\beta 1$

Since the principal isoform in NPE cells is $\alpha 2$ and dissociation from the pump is expected to affect the duration of the effects on IOP, the dissociation rates of different cardiac glycosides from the purified $\alpha 2\beta 1$ isoform were compared. The dissociation rates of digoxin, digoxigenin, DGlyN and DMe were compared using the protocol described in (20). Figure 9 depicts representative experiments for each of the four compounds and Table 4 shows the average rate-constants and half-times from three or four experiments. Evidently, the aglycone digoxigenin dissociates much faster than digoxin or any other glycone, and DMe and DGlyN also dissociate significantly slower than digoxin itself. The slow dissociation of DMe and DGlyN suggest their potential of a durable effect on IOP.

10

15

Table 4: Rates of dissociation of cardiac glycosides from the $\alpha 2\beta 1$ isoform complex.

CG	k $\pm$ SEM min ⁻¹ , n	t _{1/2} $\pm$ SEM min	p vs. digoxin
Digoxigenin	0.645 $\pm$ 0.189, 3	1.07 $\pm$ 0.23	0.0006
Digoxin	0.015 $\pm$ 0.001, 4	47.5 $\pm$ 5.05	
DGLyN	0.009 $\pm$ 0.001, 3	78.8 $\pm$ 8.73	0.02
DMe	0.0067 $\pm$ 0.004, 3	103 $\pm$ 6.12	0.001

5 **EXAMPLE 5: Digoxin derivatives with enhanced selectivity for the $\alpha 2\beta 3$ complex**

Because $\alpha 2\beta 3$ and not $\alpha 2\beta 1$ is the major isoform complex in NPE cells, it was further investigated whether the $\beta 1$, $\beta 2$, or $\beta 3$ isoform is an important factor.

10 *Molecular modeling of the digoxin bound Na,K-ATPase*

A molecular insight to the interactions of the third digitoxose residue and isoform selectivity is illustrated in Fig. 10A. The figure presents a molecular model in which the digoxin molecule (co-ordinates 3B0W) was introduced onto the high affinity ouabain bound molecule (4HYT) (14) so that the lactone and steroid portions of ouabain and digoxin overlap closely, and then a minimal energy structure was obtained. The three digitoxose residues point outwards towards both α and β subunits. The enlarged image in Fig. 10B shows the digitoxose moiety in proximity (<3.5Å) to residues AspAspArgTrp887 in L7/8 of α , the third digitoxose being close to both α Trp887 and also β Gln84. Support for this orientation towards the β subunit comes from an old observation that photoaffinity probes located in the third digitoxose of digitoxin label both α and β subunits, whereas photoaffinity probes located in other regions of cardiac glycoside molecules label only the α subunit (21, 22). As suggested by the model, α Trp887 is one of only four residues in extracellular loops that are different in $\alpha 2$ (and $\alpha 3$) from $\alpha 1$, (Gln119, Glu307, Val 881 and Trp887 in pig $\alpha 1$), and were inferred previously to be candidates for determining isoform selectivity (23) Close proximity to one of these four residues fits very well with the

notion that interactions of the third digitoxose are important for isoform selectivity, and the present findings that derivatives of the third digitoxose can enhance isoform selectivity. In $\alpha 2$, Trp887 is replaced by a threonine.

In addition, Gln84 in $\beta 1$ is replaced by Val89 in $\beta 3$ and Glu in $\beta 2$ (Fig. 10C and D). Since $\alpha 2\beta 3$ is the major isoform complex in NPE cells it seemed that by introducing larger aliphatic groups into the perhydro-1,4-oxazepine digoxin derivatives than Me and Et which were already tried, it might be possible to produce digoxin derivatives with enhanced selectivity for $\alpha 2\beta 3$ compared to $\alpha 1\beta 1$ the major isoform complex in all other cells. Another possible advantage of more hydrophobic derivatives is that they could be expected to be more permeate through the cornea and thus, potentially, effective in IOP reduction at lower concentrations than DMe or DGlyN.

Expression, purification and characterization of human $\alpha 2\beta 3$ and $\alpha 2\beta 2$ isoform complexes.

To develop compounds with higher selectivity to $\alpha 2\beta 3$ human, $\alpha 2\beta 3$ and $\alpha 2\beta 2$ human isoform complexes were expressed as described in the Methods below. Figure 11 shows a protein gel of the purified isoform complexes $\alpha 2\beta 1$, $\alpha 2\beta 2$, $\alpha 2\beta 3$ and $\alpha 1\beta 1$ before or after treatment with PNGase (in the denatured state). $\beta 1$ has 3 glycosylation sites, $\beta 3$ has two glycosylation sites while $\beta 2$ has seven glycosylation sites. The mobility order on the gel, $\beta 3 > \beta 2 > \beta 1$, fits well the predicted masses of the deglycosylated subunits of $\beta 1$, 37172.6 > $\beta 2$, 35422.2 > $\beta 3$, 33678.9. The average Na,K-ATPase activities of the purified complexes were; $\alpha 1\beta 1$, 19.3 ± 2 ; $\alpha 2\beta 1$, 18.2 ± 1.6 ; $\alpha 2\beta 2$, 7.7 ± 1.8 and $\alpha 2\beta 3$ 9.7 ± 0.26 $\mu\text{moles/min/mg protein}$ ($n=4$). Because cardiac glycosides and K ions are mutually antagonistic, an important point in relation to cardiac glycosides binding is the $K_{0.5}$ K for activation of Na,K-ATPase. The term “ $K_{0.5}$ K” as used herein means the half maximal concentration of potassium ions (K) required for activation of Na,K-ATPase activity. Fig. 12 and Table 5 shows that the apparent affinities for K are significantly different between the isoform complexes, in the order $\alpha 1\beta 1 < \alpha 2\beta 1 < \alpha 2\beta 2 < \alpha 2\beta 3$. Inhibition by digoxin is more effective for the isoforms with higher $K_{0.5}$ K (K_i $\alpha 1\beta 1 > \alpha 2\beta 1 > \alpha 2\beta 2 > \alpha 2\beta 3$), hence leading to a higher selectivity for $\alpha 2\beta 3$ over $\alpha 1\beta 1$ (Fig. 13). This increased selectivity is explained by a

lower degree of K-digoxin antagonism and is expected for all the cardiac glycosides to the same extent as for digoxin.

Table 5: $K_{0.5}$ K for activation of Na,K-ATPase activity of $\alpha 1\beta 1$, $\alpha 2\beta 1$, $\alpha 2\beta 2$ and $\alpha 2\beta 3$ isoform complexes

$\alpha 1\beta 1$ $K_{0.5}$ K-mM $\pm$ SEM	$\alpha 2\beta 1$ $K_{0.5}$ K-mM $\pm$ SEM	$\alpha 2\beta 2$ $K_{0.5}$ K-mM $\pm$ SEM	$\alpha 2\beta 3$ $K_{0.5}$ K-mM $\pm$ SEM
1.25 $\pm$ 0.03 n=4	2.72 $\pm$ 0.14 n=6	7.3 $\pm$ 0.19 n=6	6.4 $\pm$ 0.5 n=5

Synthesis and isoform selectivity of aliphatic derivatives of digoxin.

Additional set of perhydro-1,4-oxazepine digoxin derivatives with aliphatic substituents propyl (DP), iso-propyl (DIP), iso-butyl (DIB), tert- butyl (DtB) and trifluoroethyl (DMeCF₃) has been synthesized and purified. Table 6 shows results of inhibition and selectivity of the most recent aliphatic derivatives for four Na,K-ATPase isoform complexes, in comparison to digoxin itself and DMe, Fig. 14 illustrates the effects of the most selective isobutyl derivative, DIB. No significant difference was observed in $\alpha 1\beta 1$ versus $\alpha 2\beta 1$ when compared to DMe. However, for $\alpha 2\beta 3$, all of the aliphatic derivatives including DMe are significantly superior to digoxin and in the case of the isobutyl derivative the selectivity ratio reaches 16-fold. Generally, the curves for $\alpha 2\beta 2$ lie between those for $\alpha 2\beta 3$ and $\alpha 2\beta 1$. As mentioned above, the difference in $K_{0.5}$ K between the $\alpha 2\beta 1$ -3 complexes should translate into a difference in K_i as seen for digoxin in the sense $K_i \alpha 2\beta 1 > \alpha 2\beta 2 \geq \alpha 2\beta 3$. However, the increase in selectivity for $\alpha 2\beta 3$: $\alpha 1\beta 1$ is significantly higher than seen with digoxin (6.5-fold) for all these new derivatives and especially so for the isobutyl derivative, DIB (16-fold). This finding could imply that all the aliphatic derivatives, but especially DIB, interact more specifically with $\alpha 2\beta 3$ than with $\alpha 2\beta 1$. In any event the K_i of 5.8nM for inhibition of $\alpha 2\beta 3$ by DIB is lower than seen for any of the other aliphatic (or other) derivatives.

The low K_i for inhibition of $\alpha_2\beta_3$ implies that DIB could be a good inhibitor of IOP in rabbits. This was tested in experiments summarized in Fig. 15. Indeed DIB applied topically prior to 4AP effectively prevented the rise in IOP. The concentration required to fully prevent the rise in IOP ($>30\mu\text{M}$) was about 2-fold lower than required for the most effective derivative previously tested (DMe).

Table 6. Selectivity of aliphatic digoxin perhydro-1,4-oxazepine derivatives for the $\alpha_2\beta_3$ isoform complex

CG		K_i , nM $\pm$ SEM				Selectivity		n
	$\alpha_1\beta_1$	$\alpha_2\beta_1$	$\alpha_2\beta_2$	$\alpha_2\beta_3$	$\alpha_1\beta_1/\alpha_2\beta_1$	$\alpha_1\beta_1/\alpha_2\beta_2$	$\alpha_1\beta_1/\alpha_2\beta_3$	
Digoxin	268 $\pm$ 13.8	58.7 $\pm$ 5.4	58 $\pm$ 1.9	42.8 $\pm$ 3.0	4.5	4.6	6.2	7
DMe (2)	103 $\pm$ 5.6	15.3 $\pm$ 1.2	20.36 $\pm$ 1.8	10.8 $\pm$ 0.6	6.7	5.07	9.5	7
DEt (12)	137.9 $\pm$ 12.6	23.2 $\pm$ 0.9	16.4 $\pm$ 1.6	14.4 $\pm$ 1.27	5.9	8.3	9.5	4
DP (13)	87.7 $\pm$ 7.9	18.3 $\pm$ 1.68	10.5 $\pm$ 1.8	9.8 $\pm$ 1.1	4.8	8.3	8.8	5
DIP (21)	149 $\pm$ 20.7	28.9 $\pm$ 1.7	16.7 $\pm$ 1.9	10.3 $\pm$ 1.8	5.1	8.9	14.4	4
DIB (14)	92 $\pm$ 8.9	20.6 $\pm$ 1.4	10 $\pm$ 0.8	5.8 $\pm$ 0.6	4.4	9	16	5
DtB (22)	135 $\pm$ 12.1	21.6 $\pm$ 5.6	18.4 $\pm$ 1.1	16.3 $\pm$ 0.28	6.2	7.3	8.2	4
DTMS (23)	108	31.5	15	7.8	3.4	7.2	13.8	2
DMeCF ₃ (15)	119 $\pm$ 15.0	28.6 $\pm$ 0.9	18.1 $\pm$ 1.9	12.4 $\pm$ 1.5	4.1	6.5	9.6	3

In conclusion, it has now been demonstrated that modification of the third digitoxose residue of digoxin can produce derivatives with increased selectivity for $\alpha 2$ over $\alpha 1$. Compared to digoxin ($K_{i\alpha 1/\alpha 2}$ 3.44-fold), the selectivity ratio was significantly increased in the order DGlyN>DMe>DGly $\approx$ DPrN $\approx$ DSCar, reaching a maximal value of $K_{i\alpha 1/\alpha 2}$ =7.45 for DGlyN (Table 2).

Furthermore the selectivity ratio, $K_{i\alpha 2\beta 3/\alpha 1\beta 1}$, 6.5 for digoxin itself, was significantly enhanced for all the more aliphatic derivatives DP, DIP, DIB, DtB and DMeCF₃, reaching to c.16-fold for DIB.

Considering the structures of the substituents in the perhydro-1-4-oxazepine ring (Tables 1, 2 and 6), it seems that the increased $\alpha 2:\alpha 1$ selectivity (especially $\alpha 2/\beta 3$) is achieved with small R-groups having H-bonding potential (e.g., glycine, glycinamide, propionamide, semicarbazide, semithiocarbazide), or small hydrophobic groups (e.g., Me, Et, Pr, iPr and t-Bu), while larger substituents (alanine, alaninamide, serine, serinamide) improve selectivity to a lower extent, although these compounds may also be therapeutically useful. Important features of isoform selectivity are (a) $\alpha 2$ -selectivity may be restricted to digitalis glycosides with β -digitoxose residues since, for example, ouabain, an α -rhamnoside, is slightly selective for $\alpha 1$ over $\alpha 2$ and (b) the third digitoxose residue is optimal as concluded above and also in (6).

While the structures of the ouabain-bound conformations of renal Na,K-ATPase (12-14) are consistent, in general, with the observed lack of isoform selectivity of aglycones, because ouabain itself is only slightly selective for $\alpha 1$ over $\alpha 2$ (Table 2), these structures cannot explain in detail either the moderate selectivity of digoxin for $\alpha 2$ or increased selectivity for $\alpha 2$ of perhydro-1,4-oxazepine derivatives. Without wishing to be bound by any particular mechanism or theory, it is hypothesized that the relatively high selectivity of the perhydro-1,4-oxazepine derivatives of the invention (e.g., DGlyN) for $\alpha 2$ over $\alpha 1$, indicates a differential interaction with the isoform-specific residues in the exterior loops of $\alpha 2$ and $\alpha 1$. The very large difference of dissociation rates between aglycones and glycones emphasize the role of the sugars in binding to $\alpha 2$. Specific interactions with $\alpha 2$ of the modified digitoxose derivatives of DGlyN and DMe moieties are also indicated directly by the slower dissociation rates compared to digoxin (Fig. 9 and Table 4). Similarly

increased selectivity of the more aliphatic derivatives in Table 6 such as DIB for the $\alpha 2\beta 3$ complex over $\alpha 1\beta 1$ may indicate a more specific interactions with β Val89. The present findings confirm and validate the concept that modification of the third digitoxose residues can increase selectivity for the $\alpha 2$ isoform.

5 In conclusion, the $\alpha 2$ -selective digoxin derivatives described herein reduce intraocular pressure, and thus have the potential as novel drugs for control of IOP and prevention of glaucoma. When evaluated by the dose and especially duration of effects, the most $\alpha 2$ -selective compounds DMe and DGlyN are significantly more effective than either the moderately $\alpha 2$ -selective digoxin or non-selective
10 digoxigenin. Furthermore when $\alpha 2\beta 3$ selectivity is taken into account with the compounds such as DIB, superior effectiveness is observed. One important conclusion is that $\alpha 2\beta 3$ indeed plays a major role in production of the aqueous humour, as could be predicted from its prominent expression in NPE cells.

The new perhydro-1,4-oxazepine derivatives described herein may also have a
15 favorable safety profile, making them suitable as drug candidates. Local toxicity of $\alpha 2\beta 3$ -selective cardiac glycosides, namely swelling of the cornea and lens should be minimal because corneal endothelium express $\alpha 1$ and a minor amount of $\alpha 3$ but no $\alpha 2$, and lens epithelium express only $\alpha 1$. Also, systemic cardiotoxic effects should be minimal.

20 Lastly, perhydro-1,4-oxazepine derivatives of the more hydrophobic digitoxin may be even more effective than digoxin derivatives in reducing ocular hypertension, and/or as cardiotonic agents.

EXAMPLE 5 – Effects on Intra-Ocular Pressure in Rats

25 To evaluate whether the compounds of the present invention are able to control IOP in an animal model of chronic ocular hypertension, and to assess their local and systemic toxicity, ocular hypertension is being induced in rats, for example by impeding aqueous humour outflow using microbeads (24). Digoxin derivatives are added daily and IOP changes, signs of inflammation, corneal edema or lens clarity
30 are followed. For systemic toxicity the concentration of the digoxin derivatives in the blood is measured by a radioimmunoassay.

EXAMPLE 6: Experimental Section**Materials**

Escherichia (E.) coli XL-1 blue strain was used for propagation and preparation of plasmid constructs. Yeast Lytic Enzyme from ICN Biomedicals Inc (cat. 152270) was used for transformation of P. pastoris protease deficient strain SMD1165 (his4, prb1). DDM (cat. D310) and C12E8 (25% w/w, cat no. O330) were purchased from Anatrace. Synthetic SOPS (sodium salt) was obtained from Avanti Polar Lipids, and stored as a chloroform solution. BD Talon metal affinity resin (cat. 635503) was obtained from Clontech. Cholesterol, ouabain (O3125, digoxin (D6003), 4-aminopyridine, (A78403) and IB-MECA (I146)) were obtained from Sigma. Methanol HPLC grade was purchased from Baker. All the organic solvents and amines were of highest purity analytical grade.

Preparation of $\alpha 1\text{h}\beta 1$, $\alpha 1\text{h}\beta 2$, $\alpha 1\text{h}\beta 3$, $\alpha 2\text{h}\beta 1$, $\alpha 2\text{h}\beta 2$, $\alpha 2\text{h}\beta 3$, $\alpha 3\text{h}\beta 1$ constructs

Human $\beta 1$, $\beta 2$ and $\beta 3$ were cloned into the pHIL-D2 expression vector containing the human $\alpha 1$ or $\alpha 2$. pHIL-D2 expression vectors containing porcine (p) $\alpha 1$, human (h) $\alpha 1$ or human $\alpha 2$ with Hisx10 tagged porcine $\beta 1$ were previously generated (7, 9). Human $\beta 1$ (Accession: P05026), human $\beta 2$ (Accession: P14415) and human $\beta 3$ (Accession: P54709) cDNAs in pSD5 vector were a gift from K. Geering Univ. Lausanne Switzerland. The open reading frames and flanking regions of $\text{h}\beta 1$, $\text{h}\beta 2$ and $\text{h}\beta 3$ (in pSD5) were amplified separately by polymerase chain reaction (PCR) using synthetic primers containing BglII and SalI cleavage sites. Each one of the amplified fragments were digested with BglII and SalI and ligated to BglII and SalI treated plasmid pHIL-D2-(p $\alpha 1$ /His10p $\beta 1$) to generate pHIL-D2 (p $\alpha 1$ /His10h $\beta 1$ or2or3). $\text{h}\beta 1$, $\text{h}\beta 2$ and $\text{h}\beta 3$ containing fragments were excised from pHIL-D2-(p $\alpha 1$ /His10h $\beta 1$ or2or3) and subcloned into pHIL-D2-(h $\alpha 1$ /His10p $\beta 1$) or pHIL-D2-(h $\alpha 2$ /His10p $\beta 1$) to produce pHIL-D2-(h $\alpha 1$ /His10h $\beta 1$ or2or3) and pHIL-D2-(h $\alpha 2$ /His10h $\beta 1$ or2or3). The newly created plasmids were analyzed for correct integration and correct sequence of the insert by restriction enzymatic digestions and

sequencing. DNA of each construct was prepared in large quantities in E.coli XL-1 Blue for *Pichia pastoris* transformation.

Yeast transformation. Expression and purification of human Na,K-ATPase isoforms

Methods for transformation, culture of *P.pastoris* clones, protein expression of Na,K-ATPase human isoforms ($\alpha 1\beta 1$, $\alpha 2\beta 1$, $\alpha 3\beta 1$), membrane preparation, solubilization of membranes in DDM, and purification on BD-Talon beads have been described in detail (6-9, 11, 25). In initial experiments the three purified isoform complexes (0.3-0.5 mg/ml) were eluted from the BD-Talon beads in a solution containing Imidazole 170mM, NaCl 100 mM; Tricine.HCl 20 mM pH 7.4; C12E8, 0.1 mg/ml; SOPS 0.07 mg/ml cholesterol 0.01 mg/ml, glycerol 25%. In later experiments the isoforms complexes were reconstituted with purified FXYD1 on the BD-Talon beads together as described in detail in (10, 11) prior to elution of $\alpha 1\beta 1$ FXYD1, $\alpha 2\beta 1$ FXYD1 and $\alpha 3\beta 1$ FXYD1 complexes. The proteins were stored at -80°C. Protein concentration was determined with BCA (B9643 Sigma).

Assay of Na,K-ATPase activity of purified isoform complexes

Inhibition of Na,K-ATPase activity of the detergent-soluble $\alpha 1\beta 1$, $\alpha 2\beta 1$, and $\alpha 3\beta 1$ complexes by CG's was determined as described (6) using either the $\alpha\beta$ or $\alpha\beta$ FXYD1 complexes. The presence or absence of FXYD1 does not affect inhibition of Na,K-ATPase activity by cardiac glycosides (6), but strongly stabilizes the complexes (9-11). The $K_{0.5K}$ was estimated by varying K concentration in a medium containing a fixed total K+choline chloride of 60mM, and constant NaCl of 140mM. Curves were fitted to the Hill function $v = V_{max} * [S]^n / ([S]^n + K^n)$, where S is the K concentration, n is the Hill coefficient and K^n is $K_{0.5K}$. For comparison of different curves the ratio v/V_{max} for each curve was calculated and replotted. In experiments to assess inhibition of Na,K-ATPase activity by cardiac glycosides of the present invention, the percent inhibition V_{CG}/V_0 was calculated and K_i values were obtained by fitting the data to the function $V_{CG}/V_0 = K_i / ([CG] + K_i) + c$. Inhibition was estimated in 3-8 separate experiments and average K_i values $\pm$ SEM were calculated. Significance of differences between $K_{i\alpha 1}$ and $K_{i\alpha 2}$ was calculated by the unpaired Student's t-test (p values). The ratio of $K_{i\alpha 1}/\alpha 2 \pm$ SEM was calculated for each compound and p values

were calculated by comparison with digoxin. P values <0.05 were considered significant.

Dissociation rates of cardiac glycosides Purified $\alpha 2\beta 1$ FXYP1 complexes (0.3-0.5mg/ml) were incubated for 30 minutes at 37°C in a medium containing ATP, 1mM; NaCl 100 mM; MgCl₂, 4mM Histidine.HCl 25 mM pH 7.4 without (Control) or with 1μM of different cardiac glycosides. The enzyme solutions were then diluted 100-fold into a medium containing 100mM NaCl, 5mM KCl, 1mM EDTA (Tris), 0.005 mg/ml C12E8, 0.01 mg/ml SOPS, and 0.001 mg/ml cholesterol and incubated at 37°C for different lengths of time. Aliquots were removed at different times and Na,K-ATPase activity was measured in triplicate over 0.5 minutes (digoxigenin) or 2 minutes (other cardiac glycosides) in the standard activity medium containing 200μM ATP. The activity of test samples was divided by the activity of the control samples and the time-course for reversal of inhibition was analyzed by fitting the data to the function $v_t = v_{\infty} e^{-kt} + c$. Normalized curves for comparison of different experiments (e.g. as in Fig. 9) were obtained by subtracting the constant value c from each value of the activity and re-fitting the ratio $v_t/v_{\infty} = 1 - e^{-kt}$.

Synthesis of perhydro-1,4-oxazepine derivatives of digoxin

The syntheses of the different digoxin perhydro-1,4-oxazepine derivatives were performed in two steps: 1) oxidation of digoxin with sodium periodate to give an open-ring dialdehyde in the third sugar moiety and 2) reductive amination with a primary amine, in the presence of NaCNBH₃, closing a 7-membered ring to give the digoxin perhydro-1,4-oxazepine derivative. As an example, the synthesis of DGlyN is provided below. It is apparent to a person of skill in the art that the other compounds of the present invention may be prepared by the same or similar methods.

Oxidation of Digoxin with NaIO₄ (26)

In a 50ml polypropylene test tube, a solution of NaIO₄ (400 mg, 1840 μmol) in H₂O (4 ml) was added under stirring at room temperature to a suspension of digoxin (400 mg, 512 μmol) in 95% EtOH (36 ml, not fully soluble) and the mixture that immediately dissolved was allowed to stand at room temperature for 1 hr. During that

time a precipitate was formed. Precipitated NaIO_3 was removed, by centrifugation at 3,000x g for 15 min and filtration through a syringe filter (PTFE, 0.2 μm , 25 mm). The solution was concentrated in an evaporator and extracted with 40ml CHCl_3 . The organic layer was washed with 2x 8 ml water, dried over anhydrous Na_2SO_4 , filtered and evaporated in an evaporator, and high vacuum overnight to give the dialdehyde, which is dissolved in 48ml of absolute methanol to give a 10 mM solution of dialdehyde.

Reductive Amination with glycineamide hydrochloride

Glycineamide hydrochloride (28.2 mg, 256 μmoles , MW = 110.54, Aldrich) was added to the digoxin dialdehyde (180 mg = 240 μmoles) solution to give concentrations of 12mM and 10mM, respectively. The apparent pH was corrected to 5-6 with concentrated acetic acid in methanol, and the mixture was kept at room temperature for 5 min. The Schiff base that forms was reduced with NaCNBH_3 , (59.6 mg, 480 μmoles , MW= 123.95, 20mM) with stirring. Progress of the reaction was monitored by TLC (SiO_2 with acetone/ CHCl_3 (3:2)). The mixture was left for 1.5 h, the creation of DGlyN and disappearance of digoxin dialdehyde was confirmed by mass spectrometry, and the methanol was evaporated by rotavap and high vacuum overnight. Since side reactions can occur, such as acid or base induced hydrolysis of dialdehyde to bis-digitoxoside, the final product was purified. The DGlyN reaction mixture was dissolved in a minimal amount (5.4 ml) of 50% methanol, filtered through a syringe filter 0.2 μm , PTFE, and used for purification by HPLC (Fig. 2B). HPLC purification was done on a Purospher STAR RP-18e semi-prep column, eluted with a gradient of 50-80% methanol in water in 15column volumes at a flow rate of 4 ml/min. Other derivatives were purified using optimal gradients of methanol established in analytical HPLC runs (Chromolith RP-18e) prior to application to the semi-preparative column. The methanol was JT Baker HPLC gradient grade.

Additional compounds were prepared by a similar method. Their Mass Spectral data are presented in Table 1.

Digitoxin derivatives may be made by similar methods as described herein, using the digitoxin scaffold (X = H) instead of the digoxin scaffold (X = OH).

Measurement of Intraocular pressure in rabbits

Animals

New Zealand white rabbits (3-3.5 kg) about 1 year old, of either sex, were housed individually in separate cages in animal room conditions on a reversed, 12-hour dark/light cycle. For the experiments the animals were transferred to rabbit restrainers in a quiet and calm atmosphere (Fig. 1). No ocular abnormalities were detected prior or during the experiments. Animal care and treatment were subject to the approval of the institutional committee for animal experiments, Weizmann Institute IACUC permission (no 04270911-2).

10 Drug preparation and administration

Stock solutions of cardiac glycosides were dissolved in ethanol, and diluted in phosphate buffer (PBS) on each day of the experiment such that the final ethanol concentration did not exceed 1%.

Modeling

15 Digoxin (co-ordinates 3B0W) was introduced manually into the structure of pig kidney Na,K-ATPase bound with ouabain (4HYT) so that the steroid and lactone moieties of ouabain and digoxin superimposed as closely as possible, see ref. The structure file with bound digoxin was then submitted to the YASARA Energy Minimization Server. The structural figure was prepared with PyMOL.

20

Intraocular pressure and corneal thickness measurements

IOP (mm Hg) of rabbits was measured using a calibrated Pneumatonometer (Model 30, Reichert technologies, Fig. 1). A local anesthetic Oxybuprocaine HCl (0.4%, 25µl) was applied to each cornea about a minute before IOP measurements. Two baseline IOP readings were taken before topical administration of the CG (or PBS as control) and after half an hour (Zero time). The readings of the two measurements were almost identical, suggesting that the CG's had no effect on the basal IOP. At zero time one drop of 4AP (40mg/ml, 30µl) or IB-MECA (1µM, 30µl) was administered to both eyes of each rabbit IOP measurements were made at different times as indicated in each experiment. In the experiments for which the IOP was elevated for several hours, 4AP was added every 1.5 hours or IB-MECA every 2

hours. The Pneumatonometer readings were accepted when the standard deviation of the value XmmHg was between 0.1- 0.4mmHg i.e $X \pm 0.1-0.4$ mmHg, representing a possible error of 6-13% compared to the minimal 3mm Hg increase and 1.6-6.7% compared to the maximal 6 mm Hg increase in IOP induced by 4AP or IB-MECA.

- 5 Each experiment was repeated two or three times with similar results. In all cases the figures depict the average effect on IOP (i.e for four or six eyes) compared to control $\pm$ SEM. Where error bars are not seen in the figures, the errors are smaller than the symbols used. Significance of differences from the control was calculated by the unpaired Students t-test (p values). p values <0.05 were considered significant.
- 10 Corneal thickness (μ m) was measured using an ultrasonic pachymeter (Sonogage pachometer, Cleveland, USA), before and during the experiment with CG and 4AP treatments. The values represent averages of three independent measurements for each eye.

15 Abbreviations:

IOP, intra-ocular pressure;

CG, cardiac glycoside;

4AP, 4-aminopyridine.

- 20 While certain embodiments of the invention have been illustrated and described, it will be clear that the invention is not limited to the embodiments described herein. Numerous modifications, changes, variations, substitutions and equivalents will be apparent to those skilled in the art without departing from the spirit and scope of the present invention as described by the claims, which follow.

References

1. Simon KA & Bonting SL (1962) Possible usefulness of cardiac glycosides in treatment of glaucoma. *Arch Ophthalmol* 68:227-234.
- 5 2. Ferraiolo BL & Pace DG (1979) Digoxin-induced decrease in intraocular pressure in the cat. *Eur J Pharmacol* 55(1):19-22.
3. Wetzel RK & Sweadner KJ (2001) Immunocytochemical localization of NaK-ATPase isoforms in the rat and mouse ocular ciliary epithelium. *Invest Ophthalmol Vis Sci* 42(3):763-769.
- 10 4. Despa S, Lingrel JB, & Bers DM (2012) Na(+)/K(+)-ATPase alpha2-isoform preferentially modulates Ca2(+) transients and sarcoplasmic reticulum Ca2(+) release in cardiac myocytes. *Cardiovasc Res* 95(4):480-486.
5. Wasserstrom JA & Aistrup GL (2005) Digitalis: new actions for an old drug. *American journal of physiology. Heart and circulatory physiology* 289(5):H1781-1793.
- 15 6. Katz A, *et al.* (2010) Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. *J Biol Chem* 285(25):19582-19592.
7. Cohen E, *et al.* (2005) Purification of Na+,K+-ATPase expressed in *Pichia pastoris* reveals an essential role of phospholipid-protein interactions. *J Biol Chem* 280(17):16610-16618.
- 20 8. Haviv H, *et al.* (2007) Stabilization of Na(+),K(+)-ATPase purified from *Pichia pastoris* membranes by specific interactions with lipids. *Biochemistry* 46(44):12855-12867.
9. Lifshitz Y, *et al.* (2007) Purification of the human alpha2 Isoform of Na,K-ATPase expressed in *Pichia pastoris*. Stabilization by lipids and FXYD1. *Biochemistry* 46(51):14937-14950.
- 25 10. Mishra NK, *et al.* (2011) FXYD proteins stabilize Na,K-ATPase: amplification of specific phosphatidylserine-protein interactions. *J Biol Chem* 286(11):9699-9712.
- 30 11. Kapri-Pardes E, *et al.* (2011) Stabilization of the alpha2 isoform of Na,K-ATPase by mutations in a phospholipid binding pocket. *J Biol Chem* 286(50):42888-42899.
12. Ogawa H, Shinoda T, Cornelius F, & Toyoshima C (2009) Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. *Proceedings of the National Academy of Sciences of the United States of America* 106(33):13742-13747.
- 35 13. Yatime L, *et al.* (2011) Structural insights into the high affinity binding of cardiotonic steroids to the Na+,K+-ATPase. *J Struct Biol* 174(2):296-306.
14. Laursen M, Yatime L, Nissen P, & Fedosova NU (2013) Crystal structure of the high-affinity Na+,K+-ATPase-ouabain complex with Mg2+ bound in the cation binding site. *Proceedings of the National Academy of Sciences of the United States of America* 110(27):10958-10963.
- 40 15. Adamczyk M, Grote J, & Mattingly PG (1995) Digoxin dialdehyde reductive aminations. Structure proof of the perhydro-1,4-oxazepine product. *Steroids* 60(11):753-758.
- 45 16. Socci RR, Chu E, Bayorh MA, & Chu TC (2003) 4-aminopyridine transiently increases intraocular pressure in rabbits. *Pharmacology* 69(2):108-114.


17. Crambert G, *et al.* (2000) Transport and pharmacological properties of nine different human Na, K-ATPase isozymes. *J Biol Chem* 275(3):1976-1986.
18. Carre DA, Mitchell CH, Peterson-Yantorno K, Coca-Prados M, & Civan MM (2000) Similarity of A(3)-adenosine and swelling-activated Cl(-) channels in
5 nonpigmented ciliary epithelial cells. *Am J Physiol Cell Physiol* 279(2):C440-451.
19. Li A, Leung CT, Peterson-Yantorno K, Mitchell CH, & Civan MM (2010) Pathways for ATP release by bovine ciliary epithelial cells, the initial step in purinergic regulation of aqueous humor inflow. *Am J Physiol Cell Physiol*
10 299(6):C1308-1317.
20. Yoda A & Yoda S (1974) Structure-activity relationships of cardiotonic steroids for the inhibition of sodium- and potassium-dependent adenosine triphosphatase. 3. Dissociation rate constants of various enzyme-cardiac glycoside complexes formed in the presence of sodium, magnesium, and
15 adenosine triphosphate. *Molecular pharmacology* 10(3):494-500.
21. Hall C & Ruoho A (1980) Ouabain-binding-site photoaffinity probes that label both subunits of Na⁺,K⁺-ATPase. *Proceedings of the National Academy of Sciences of the United States of America* 77(8):4529-4533.
22. Ruoho AE & Hall CC (1980) The use of photolabels to probe the ouabain
20 binding site of the (Na, K)-ATPase. *Annals of the New York Academy of Sciences* 346:90-103.
23. Katz A, *et al.* (2014) Digoxin Derivatives with Enhanced Selectivity for the alpha2 Isoform of Na,K-ATPase: EFFECTS ON INTRAOCULAR PRESSURE IN RABBITS. *J Biol Chem* 289(30):21153-21162.
24. Sappington RM, Carlson BJ, Crish SD, & Calkins DJ (2010) The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. *Invest Ophthalmol Vis Sci* 51(1):207-216.
25
25. Strugatsky D, Goldshleger R, Bibi E, & Karlsh SJ (2003) Expression of Na,K-ATPase in *P. pastoris*: Fe²⁺-catalyzed cleavage of the recombinant enzyme. *Annals of the New York Academy of Sciences* 986:247-248.
30
26. Satoh D & Aoyama K (1970) Studies on Digitalis Glycosides. XXXI. Stepwise Degradation of Polydigitoxosides of Cardenolides. *Chem. Pharm. Bull.* 18(1):94-99.

CLAIMS

What is Claimed is:

5

1. A compound represented by the structure of general formula (I):




I

- 10 R is selected from the group consisting of OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -(CR^bR^c)_nSi(R^a)₃, -(CR^bR^c)_n-C(=Y)-NR¹R², -(CR^bR^c)_n-C(=Y)-NHOH, -(CR^dR^e)_n-C(=Y)-COOR³; and -NHC(=Y)NR¹R²;
Y is O or S;
X is H or OH;
- 15 R¹, R² and R³ are each independently H or a C₁-C₄ alkyl;
R^a is a C₁-C₄ alkyl;
R^b, R^c and R^d are each independently selected from H, a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl;
R^e is selected from a C₁-C₄ alkyl and a C₁-C₄ hydroxyalkyl; and
- 20 n is 0, 1 or 2;
including salts, hydrates, solvates, polymorphs, geometrical isomers, optical isomers, enantiomers, diastereomers, and mixtures thereof.
2. The compound of claim 1, wherein R is selected from the group consisting of CZ₃, -CZ₂CZ₃, -(CH₂)₂CH₃, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃ and -C(CH₃)₃, wherein each Z is independently at each
25 occurrence H or halogen.

3. The compound of claim 2, wherein each Z is H or F.
4. The compound of claim 1, wherein R^1 , R^2 and R^3 are each H.
5. The compound of claim 1, wherein n is 1 or 2.
6. The compound of claim 1, wherein Y is O.
- 5 7. The compound of claim 1, wherein R is selected from the group consisting of -
CH₂-C(=O)-NH₂, -CH₃, -(CH₂)₂-C(=O)-NH₂, NHC(=O)-NH₂, OH, -
CH(CH₃)CONH₂, -CH(CH₂OH)COOH, -CH(CH₂OH)CONH₂, -CH₂CH₃, -CH₂CH₂CH₃,
-CH₂C(CH₃)₂, -CH₂CF₃, -CH₂CONHOH, -NHCSNH₂, -CH₂CH₂F, -CH(CH₂)₃, -
C(CH₃)₃, and -CH₂-Si(CH₃)₃.
- 10 8. The compound of claim 1, wherein X is OH, and the compound is a digoxin
derivative.
9. The compound of claim 8, wherein R is -CH₂-C(=O)-NH₂ (compound 1).
10. The compound of claim 8, wherein R is -CH₃ (compound 2).
11. The compound of claim 8, wherein R is -(CH₂)₂-C(=O)-NH₂ (compound 3).
- 15 12. The compound of claim 8, wherein R is -NHC(=O)-NH₂ (compound 4).
13. The compound of claim 8, wherein R is OH (compound 6).
14. The compound of claim 8, wherein R is -CH(CH₃)CONH₂ (compound 8).
15. The compound of claim 8, wherein R is -CH(CH₂OH)COOH (compound 9).
16. The compound of claim 8, wherein R is -CH(CH₂OH)CONH₂ (compound 10).
- 20 17. The compound of claim 8, wherein R is -CH₂CH₃ (compound 12).
18. The compound of claim 8, wherein R is -(CH₂)₂CH₃ (compound 13).
19. The compound of claim 8, wherein R is -CH₂CH(CH₃)₂ (compound 14).
20. The compound of claim 8, wherein R is -CH₂CF₃ (compound 15).
21. The compound of claim 8, wherein R is -CH₂C(=O)-NHOH (compound 17).
- 25 22. The compound of claim 8, wherein R is -NHCSNH₂ (compound 18).
23. The compound of claim 8, wherein R is -CH₂CH₂F (compound 19).
24. The compound of claim 8, wherein R is -CH(CH₃)₂ (compound 21).

25. The compound of claim 8, wherein R is $-\text{C}(\text{CH}_3)_3$ (compound **22**).
26. The compound of claim 8, wherein R is methyl(trimethylsilyl) ($-\text{CH}_2-\text{Si}(\text{CH}_3)_3$) (compound **23**).
27. The compound of claim 1, wherein X is H, and the compound is a digitoxin derivative.
28. The compound of claim 1, wherein the compound is selective for $\alpha 2$ isoform of Na,K-ATPase over other isoforms of Na,K-ATPase.
29. The compound of claim 28, wherein the compound is selective for the $\alpha 2\beta 1$, $\alpha 2\beta 2$ and/or $\alpha 2\beta 3$ isoform of Na,K-ATPase over the $\alpha 1\beta 1$ isoform of Na,K-ATPase.
30. A pharmaceutical composition comprising a compound of formula (I) according to any of the preceding claims, and a pharmaceutically acceptable carrier or excipient.
31. The composition of claim 30, which is an ophthalmic composition suitable for topical application to the eye in the form of an eye-drop solution, an ointment, a suspension, a gel or a cream.
32. The composition of claim 30, further comprising at least one pharmaceutically acceptable agent selected from one or more of a stabilizer, a preservative, a chelating agent, a viscosity modifying agent, a buffering agent, and pH adjusting agent.
33. A method for reducing ocular hypertension, or for treating glaucoma, comprising the step of administering to a subject in need of such a treatment an effective amount of a compound according to any one of claims 1 to 29, or a pharmaceutical composition according to any one of claims 30 to 32.
34. Use of a compound according to any one of claims 1 to 29, or a pharmaceutical composition according to any one of claims 30 to 32, for the manufacture of a medicament for the reduction of ocular hypertension, or for treating glaucoma.
35. The method of claim 33, or the use of claim 34, wherein the ocular hypertension is associated with glaucoma.

36. A method for reducing ocular hypertension, or for treating glaucoma, comprising the step of administering to a subject in need of such a treatment an effective amount of a compound represented by the structure of formula (IA):



5 wherein

R is selected from the group consisting of OH, C₁-C₆ alkyl, C₁-C₆ haloalkyl, -
 (CR^bR^c)_nSi(R^a)₃, -(CR^bR^c)_n-C(=Y)-NR¹R², -(CR^bR^c)_n-C(=Y)-NHOH,
 -(CR^dR^e)_n-C(=Y)-COOR³; -NHC(=Y)NR¹R²; and -(CR^bR^c)_n-NH₂;

Y is O or S;

10 X is H or OH;

R¹, R² and R³ are each independently H or a C₁-C₄ alkyl;

R^a is a C₁-C₄ alkyl;

R^b, R^c, R^d and R^e are each independently selected from H, a C₁-C₄ alkyl and a
 C₁-C₄ hydroxyalkyl; and

15 n is 0, 1 or 2;

including salts, hydrates, solvates, polymorphs, geometrical isomers,
 optical isomers, enantiomers, diastereomers, and mixtures thereof.

37. The method of claim 36, wherein R is selected from the group consisting of -
 CH₂-C(=O)OH, -CH₂-C(=O)-OCH₃ and CH₂-CH₂-NH₂.

20 **38.** The method of claim 36, wherein X is OH, and the compound is a digoxin
 derivative.

39. The method of claim 38, wherein R is -CH₂-C(=O)OH (compound **5**).

40. The method of claim 38, wherein R is -CH₂-C(=O)-OCH₃ (compound **7**).

41. The method of claim 38, wherein R is -CH₂-CH₂-NH₂ (compound **11**).

42. The method of claim 36, wherein X is H, and the compound is a digitoxin derivative.
43. The method of any one of claims 36 to 42, wherein the compound is selective for $\alpha 2$ isoform of Na,K-ATPase over other isoforms of Na,K-ATPase.
- 5 44. The method of claim 43, wherein the compound is selective for the $\alpha 2\beta 1$, $\alpha 2\beta 2$ and/or $\alpha 2\beta 3$ isoform of Na,K-ATPase over the $\alpha 1\beta 1$ isoform of Na,K-ATPase.
45. The method of any one of claims 36 to 44, wherein the compound of formula (IA) is administered in a pharmaceutical composition comprising said compound, and a pharmaceutically acceptable carrier or excipient.
- 10 46. The method of claim 45, wherein said composition is an ophthalmic composition suitable for topical application to the eye in the form of an eye-drop solution, an ointment, a suspension, a gel or a cream.
47. Use of a compound of formula (IA) as defined in claim 36, or a pharmaceutical composition comprising such compound, for the manufacture of a medicament
- 15 for the reduction of ocular hypertension, or for treating glaucoma.
48. The method of any of claims 36 to 46, or the use of claim 47, wherein the ocular hypertension is associated with glaucoma.
49. A cardiotonic composition comprising of a compound of formula (I) according to one any of claims 1 to 29, or a compound of formula (IA) as defined in claim
- 20 36.
50. Use of a compound of formula (I) according to any one of claims 1-29, or a compound of formula (IA) as recited in claim 36, as a cardiotonic agent.

METHODS:

- New Zealand white Rabbits
- Acute IOP elevation:
 - 4AP (40 mg/ml, 30 μ l)
 - IB-MECA (1 μ M, 30 μ l)
- IOP measurement
 - using Pneumatonometer




Fig. 1




Fig. 2A




Fig. 2B

Fig. 3A





Fig. 3B






Fig. 4





Fig.5B




Fig. 5C

Fig. 5D





Fig. 5E






Fig. 6




Fig. 7A




Fig. 7B




Fig. 7C




Fig. 8A

Fig. 8B





Fig. 8C






Fig. 9




Fig. 10A




Fig. 10B

Fig. 10C





Fig. 10D






Fig. 11




Fig. 12




Fig. 13





Fig. 14

**Fig. 15**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2014/050773

A. CLASSIFICATION OF SUBJECT MATTER IPC (2014.01) C07J 19/00, A61K 31/704, A61K 31/395, A61P 27/06 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC (2014.01) C07J 19/00, A61K 31/704, A61K 31/395, A61P 27/06 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Databases consulted: THOMSON INNOVATION, CAPLUS, REGISTRY, Google Scholar, FamPat database Search terms used: intraocular pressure, glaucoma, cardiogenic agents ,intraocular , glaucoma, eye, hypertension , digoxin, digitoxin, digitoxigenin, isoform		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	"SELECTIVITY OF DIGITALIS GLYCOSIDES FOR ISOFORMS OF HUMAN NA,K-ATPASE " THE JOURNAL OF BIOLOGICAL CHEMISTRY, 285, 19582-19592. ADRIANA KATZ, Yael LIFSHITZ, ELIZABETH BAB-DINITZ, EINAT KAPRI-PARDES, RIVKA GOLDSHLEGER, DANIEL M. TAL AND STEVEN J. D. KARLISH 18 Jun 2010 (2010/06/18) whole document	1-50
Y	EFFECT OF SYSTEMIC DIGITALIS APPLICATION ON INTRAOCULAR PRESSURE", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY ,, 219(2), PP. 76-9 IN GERMAN, CODEN: GACODL ISSN: 0721-832X; HARDT B. W., JOHNNEN R., FAHLE M 31 Aug 1982 (1982/08/31) abstract	1-50
Y	WO 2007016656 A2 BIONAUT PHARMACEUTICALS, KHODADOUST MEHRAN 02 Aug 2007 (2007/08/02) whole document	1-50
Y	WO 2006044916 A2 BIONAUT PHARMACEUTICALS INC; KHODADOUST MEHRAN? 27 Apr 2006 (2006/04/27) whole document	1-50
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 06 Nov 2014		Date of mailing of the international search report 18 Nov 2014
Name and mailing address of the ISA: Israel Patent Office Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel Facsimile No. 972-2-5651616		Authorized officer BERKOWITZ Tzipora Telephone No. 972-2-5651656

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IL2014/050773

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
WO 2007016656 A2	02 Aug 2007	WO 2007016656 A2	08 Feb 2007
		WO 2007016656 A3	07 Jun 2007
		WO 2007016656 A8	19 Jul 2007
		EP 1928470 A2	11 Jun 2008
		EP 1928470 A4	15 Sep 2010
		US 2011076278 A1	31 Mar 2011
WO 2006044916 A2	27 Apr 2006	WO 2006044916 A2	27 Apr 2006
		WO 2006044916 A3	04 Jan 2007
		EP 1812010 A2	01 Aug 2007
		US 2006135443 A1	22 Jun 2006